is a company specializing primarily in the sales of pharmaceutical raw materials and intermediates, with research and development and production as supplementary activities. The company boasts a team of technical and managerial talents with extensive experience in R&D and large-scale production. Not only can the company develop small-batch new drug products, but it also has a solid cooperative foundation with various companies, enabling it to meet customer demands for products ranging from kilogram to tonnage levels. CanRui Pharmaceuticals adheres to the service principle of "credibility first, customer supreme," and is dedicated to providing high-quality products and technical services to the domestic and international raw material pharmaceutical markets. The company's current main products include Vandetanib, Palonosetron Hydrochloride, Terbinafine Hydrochloride, Axitinib, Azasetron Hydrochloride, Saxagliptin Monohydrate, Aprepitant, Fosaprepitant, Erlotinib Hydrochloride, Letrozole, Sitagliptin Phosphate Monohydrate, Capecitabine, Bicalutamide, Eszopiclone, Entecavir Monohydrate, Linagliptin, Isoladipine Maleate, Ramelteon, Zabularin, and more. *All products of this company will not be supplied to any regions or countries where the product is protected by patents. Any legal liabilities and consequences arising from this shall be borne by the purchaser.